The use of PSA as a biomarker for detecting prostate cancer caused a sharp increase in PCa incidence and lowered the number of metastatic or locally advanced tumors diagnosed (the specificity and sensitivity range from 20% to 40% and from 70% to 90%, respectively). The gene discussed is KLK3; the disease is prostate cancer.